Peter M. Voorhees, MD

Treatment of Newly Diagnosed, Transplant-Eligible Multiple Myeloma

08/29/2020

03/09/2020

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis

Purpose of the Study: Daratumumab (DARA), a human CD38 mAb, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for MM. In phase 3 studies, DARA-based regim...

Larry D. Anderson Jr.;

Daniela Hoehn ;

Nitya Nathwani ;

Thomas S. Lin ;

Nina Shah ;

Paul G. Richardson ;

Yvonne A. Efebera ;

Caitlin L. Costello , MD;

Andrzej Jakubowiak ;

Tanya M. Wildes ;

Ajai Chari , MD;

Robert Z. Orlowski ;

Peter M. Voorhees , MD;

Kenneth G. Shain ;

Johnathan L. Kaufman ;

Ander J. Cowan ;

Jacob Laubach ;

Sean Murphy ;

Douglas W. Sborov ;

Yana Lutska ;

Brandi Reeves ;

Huiling Pei ;

Cesar Rodriguez ;

Jon Ukropec ;

Rebecca Silbermann ;

Jessica Vermeulen ;

Luciano J. Costa ;

Carla de Boer ;

10/22/2019

Videos

Evolving Frontline Therapies for Patients With Newly Diagnosed Multiple Myeloma

08/22/2023

Peter M. Voorhees , MD;

Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Peter Voorhees, MD, discusses...

08/22/2023

Oncology

Videos

Examining CD38-Targeting Antibody Therapies for Patients With Newly Diagnosed Transplant-Ineligible Multiple Myeloma

08/28/2023

Peter M. Voorhees , MD;

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Peter Voorhees, MD, analyzes data on the use of CD38-targeting antibodies for patients with newly diagnosed transplant-ineligible multiple myeloma.

At the 2023 Great Debates &...

08/28/2023

Oncology

Smoldering Multiple Myeloma: Not to Treat

Peter M. Voorhees , MD;

08/29/2020